Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty
- 1 June 1999
- journal article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 83 (11) , 1569-1570
- https://doi.org/10.1016/s0002-9149(99)00151-4
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Meeting HighlightsCirculation, 1998
- Combined Accelerated Tissue-Plasminogen Activator and Platelet Glycoprotein IIb/IIIa Integrin Receptor Blockade With Integrilin in Acute Myocardial InfarctionCirculation, 1997
- ACC/AHA guidelines for the management of patients with acute myocardial infarctionJournal of the American College of Cardiology, 1996
- The Effects of Tissue Plasminogen Activator, Streptokinase, or Both on Coronary-Artery Patency, Ventricular Function, and Survival after Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab thrombolytic therapy: Results of the thrombolysis and angioplasty in mycardial infaraction (TAMI) 8 pilot studyJournal of the American College of Cardiology, 1993
- Present status of rescue coronary angioplasty: Current polarization of opinion and randomized trialsJournal of the American College of Cardiology, 1992
- Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group.Circulation, 1990
- Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinaseJournal of the American College of Cardiology, 1988